Stocks · News reference
Organigram Affirm Global FY2026 Revenue expected to be more than $255.197M vs $241.360M Est
Organigram Global (NASDAQ:OGI) affirm FY2026 Revenue expected to be more than $255.197M vs $241.360M Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Organigram Global shares are trading higher after the company reported better-than-expected Q3 sales results and issued strong FY26 revenue guidance.
OrganiGram Holdings Q3 Sales $76.413M Beat $67.660M Estimate
OrganiGram Holdings (NASDAQ:OGI) reported quarterly sales of $76.413 million which beat the analyst consensus estimate of $67.660 million by 12.94 percent. This is a 49.41 percent increase over sales of $51.142 million
Organigram Global Q3 Sales $105.782M Beat $96.870M Estimate
Organigram Global (TSX:OGI) reported quarterly sales of $105.782 million which beat the analyst consensus estimate of $96.870 million by 9.20 percent. This is a 49.43 percent increase over sales of $70.792 million the
Organigram Maintains Cannabis Market Lead Ahead Of Q3 Results
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity